Cox-2 Inhibitors are nonsteroidal anti-inflammatory drugs used to relieve pain and inflammation. COX-2 inhibitors are being studied in the prevention of colon polyps, and as anticancer drugs. Also called cyclo-oxygenase-2 inhibitor.
Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.
With cancer, researchers don't believe "you are what you eat"; that disease is always a direct result of what is, or what isn't, on your dinner plate.
Doctors in the UK are being warned that commonly used painkillers such as ibuprofen can increase the risk of heart attacks if taken over long periods.
Two major studies by experts in the U.S. and Australia have provided new evidence of the cardiovascular and kidney risks attached to both COX-2 inhibitors and NSAID painkillers.
TV advertising of prescription drugs may be prompting more people to visit their doctors rather than substantially increasing sales of advertised drugs, according to research led by the Medical University of South Carolina (MUSC).
A researcher from Dartmouth reports the results of a clinical trial that shows that the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (VIOXX.) reduces the risk of colorectal adenomas, or polyps.
An international team of scientists reports that a single 400-milligram daily dose of celecoxib, commonly called Celebrex. and manufactured by Pfizer, significantly reduced recurrence of adenomas, or pre-malignant colon tumors - within three years of previous adenoma removal.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been the most popular treatment for arthritis - despite their association with gastrointestinal (GI) complications, including bleeding ulcers and death.
An early phase study pairing an experimental targeted therapy with a common anti-inflammatory produced promising results in patients with advanced lung cancer, researchers at UCLA's Jonsson Cancer Center reported.
COX-1 and COX-2 enzymes may be blocked by pain medications such as Advil and Vioxx in a more complex manner than was previously understood, a Queen's University study has found.
UCLA/VA researchers found that for arthritis patients, taking a combination of two drugs may be most effective in protecting against stomach upset called dyspepsia, which is a side effect of common pain medications.
Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.
In their quest to determine whether immune system surveillance guards against brain tumor development, researchers at The University of Texas M. D. Anderson Cancer Center have found that allergies and asthma that stimulate inflammation may be protective, but use of antihistamines to control the inflammation could eliminate that protection.
According to two studies published in the American Gastroenterological Association (AGA) journal Clinical Gastroenterology and Hepatology, prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease (IBD) and are not likely to cause symptom flare-ups in IBD patients in remissions
Drug company Pfizer Inc., the maker of Celebrex, will pay for an international study of 20,000 people.
There is no evidence to back up claims that the new generation of anti-inflammatory drugs (COX-2 inhibitors) are less harmful to the stomach lining than many traditional anti-inflammatory drugs, concludes a study in the British Medical Journal.
Since smoking became popular in America in the 1930s, lung cancer rates have continued to climb. Today, it is still the leading cause of cancer-related deaths, with totals more than the other five leading cancers combined.
Their findings that a chemical imbalance might underlie such damage could also lead to the development of anti-inflammatory drugs without the adverse side effects, the researchers said.
A close structural relative of the celebrated COX-2 inhibitor celecoxib (brand name: Celebrex) is a potent tumor fighter, able to wipe out tumor cells that are resistant to conventional chemotherapies, according to an interdisciplinary team of researchers from the University of Southern California.
University of Pennsylvania School of Medicine researchers have found additional evidence that may help explain how selective inhibitors of COX-2 might predispose individuals to heart disease and stroke.